BioLineRx shares new data from its Phase 2 pancreatic cancer trial, showing strong response rates and durable outcomes with motixafortide combination.

A new study employing novel single-cell multimodal data revealed key insights into the tumor microenvironment predictive of NSCLC treatment response.

A new targeted cancer drug, DB-1310, is showing early signs of effectiveness in patients with advanced solid tumors that have ...

Researchers led by Université de Montréal pathology and cell-biology professor Marc Therrien have identified major structural ...

The Cocoon® (from Lonza) is a functionally closed, sterile, efficient manufacturing platform, which combined with our decentralized manufacturing strategy and rapid release testing, enables delivery ...